Supplementary Files
Keywords
How to Cite
Abstract
Community acquired pneumonia (CAP) is one of the first mortality causes in Colombia it accounts for 13 of every 100,000 deaths per year. Its principal etiologic agent is still Streptococcus pneumoniae, followed by Haemophilus influenzae and Staphylococcus aureus. Several risk factors have been described for CAP and specific pathoghens, such as coomorbidities and exposition factors. Diagnosis is made by clinical findings associated to laboratory workup and radiological evidence. CURB-65 and PSI are the most known and used tools that, in association with clinical evaluation, calculate the mortality risk and evaluate the setting of management. This literature review aims to consider crucial aspects for the correct assessment of CAP patients, biomarkers used in CAP, particular situations such as severe CAP as well as prevention strategies.
2. Bennett J, Dolin R, Blaser M. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier; 2014.
3. Arshad H, Fasanya A, Cheema T, Singh AC. Acute pneumonia. Crit Care Nurs Q. 2016 Apr-Jun;39(2):148-60.
4. Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F. Community-acquired pneumonia: New guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol. 2010;46(10):543-58.
5. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2(1537-6591):S27-72.
6. Isturiz RE, Luna CM, Ramírez J. Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010 Oct;14(10):e852-6.
7. Vélez L, Rueda Z, Aguilar Y, Ortega H, Montufar FE, Arroyave M, et al. Caracterización clínica y etiológica de NAC, Valle de Aburrá. Infectio. 2006;10:103
8. Caballero A, Polanía E, Gordillo M, Martínez O, Torrado E, et al. Agentes etiológicos de Neumonía Adquirida en Comunidad (NAC) en pacientes adultos inmunocompetentes que consultan al servicio de urgencias de la Clínica Reina Sofía, Bogotá, 2006-2007. Rev Médica Sanitas. 2010;13:8-18.
9. Robledo J, Sierra P, Bedoya F, Londoño A, Porras A, Luján M, et al. Neumonías adquiridas en la comunidad en adultos: un estudio etiológico prospectivo con énfasis en el diagnóstico. Rev Colomb Neumol. 2003;15:7-14.
10. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin‐resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(S5):S378-85.
11. Obed M, García-Vidal C, Pessacq P, Mykietiuk A, Viasus D, Cazzola L, et al. Características clínicas y pronóstico de la neumonía adquirida en la comunidad causada por Staphylococcus aureus resistente a la meticilina. Enferm Infecc Microbiol Clin. 2014 Jan;32(1):23-7.
12. Instituto Nacional de Salud-Grupo de Microbiología. Informe nacional de SIREVA II Colombia 1994-2005 [internet]. Disponible en: https://www.ins.gov.co/buscador-eventos/Informacin %20de %20laboratorio/Informe %20Nacional %20SIREVA %20II %20Colombia %201994-2005 %20Streptococcus %20pneumoniae.pdf
13. Álvarez MF, Ramírez Quintero JD, Mejía SA. Neumonía y neumotórax espontáneo por tuberculosis. Acta Med Colomb [internet]. 2016;41(1):62-6. Disponible en: http://www.scielo.org.co/pdf/amc/v41n1/v41n1a12.pdf
14. Gutiérrez CJ, Zamudio RS. Neumonía tuberculosa: Reporte de 20 casos y estudio caso-control. Acta Med Peru. 2001;18(1):5-11.
15. Longo D, Fauci A, Kasper D, Hauser S. Harrison principios de medicina interna. New York: McGraw Hill; 2012.
16. Macfarlane J. CURB-65 [Internet]. Disponible en: https://www.mdcalc.com/curb-65 score-pneumonia-severity
17. Michael J. Fine. PSI/PORT SCORE [Internet]. Disponible en: https://www.mdcalc.com/psi-port-score-pneumonia-severity-index-cap#creator-insights
18. Alan M, Grolimund E, Kutz A, Christ-Crain M, Thomann R, Falconnier C, et al. Clinical risk scores and blood biomarkers as predictors of long-term outcome in patients with community-acquired pneumonia: a 6-year prospective follow-up study. J Intern Med. 2015;278(2):174-84.
19. Yeon Lee S, Cha S-I, Seo H, Oh S, Choi K-J, Yoo S-S, et al. Multimarker Prognostication for Hospitalized Patients with Community-acquired Pneumonia. Intern Med. 2016;55(8):887-93.
20. Viasus D, Del Río-Pertuz G, Simonetti AF, García-Vidal C, Acosta-Reyes J, Garavito A, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. J Infect. 2016;72(3):273-82.
21. Aujesky D, Fine MJ. The pneumonia severity index: a decade after the initial derivation and validation. Clin Infect Dis. 2008;47 Suppl 3:S133-9.
22. Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, Von Baum H, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31(2):349-55.
23. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011;52(suppl. 4):346-50.
24. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600-7.
25. Leoni D, Rello J. Severe community-acquired pneumonia: optimal management. Curr Opin Infect Dis. 2017;30(2):240-7.
26. Pereira JM, Azevedo A, Basílio C, Mergulhão P, Paiva JA. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? Rev Port Pneumol. 2016;22(6):308-14. doi: 10.1016/j.rppnen.2016.03.012
27. Julián-Jiménez A, González del Castillo J, Candel Fj. Usefulness and prognostic value of biomarkers in patients with community-acquired pneumonia in the emergency department. Med Clin (Barc). 2017;148(11):501-10. doi: 10.1016/j.medcli.2017.02.024
28. Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest. 2016 Jan;149(1):209-19.
29. Manuel J, Mu G, César J, Rincón G, Alí A, Cano CA, et al. Guías para la inmunización del adolescente y adulto en Colombia: Documento de actualización, 2016. Infectio [Internet]. 2016;20(4):192-210. Disponible en: http://www.scielo.org.co/pdf/inf/v20n4/0123-9392-inf-20-04-00192.pdf
This journal is registered under a Creative Commons Attribution 4.0 International Public License. Thus, this work may be reproduced, distributed, and publicly shared in digital format, as long as the names of the authors and Pontificia Universidad Javeriana are acknowledged. Others are allowed to quote, adapt, transform, auto-archive, republish, and create based on this material, for any purpose (even commercial ones), provided the authorship is duly acknowledged, a link to the original work is provided, and it is specified if changes have been made. Pontificia Universidad Javeriana does not hold the rights of published works and the authors are solely responsible for the contents of their works; they keep the moral, intellectual, privacy, and publicity rights.
Approving the intervention of the work (review, copy-editing, translation, layout) and the following outreach, are granted through an use license and not through an assignment of rights. This means the journal and Pontificia Universidad Javeriana cannot be held responsible for any ethical malpractice by the authors. As a consequence of the protection granted by the use license, the journal is not required to publish recantations or modify information already published, unless the errata stems from the editorial management process. Publishing contents in this journal does not generate royalties for contributors.